KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Change in Account Payables (2018 - 2025)

Esperion Therapeutics' Change in Account Payables history spans 8 years, with the latest figure at -$12.4 million for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 233.76% year-over-year to -$12.4 million; the TTM value through Dec 2025 reached $20.9 million, up 68.26%, while the annual FY2025 figure was $20.9 million, 68.26% up from the prior year.
  • Change in Account Payables reached -$12.4 million in Q4 2025 per ESPR's latest filing, down from $2.9 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $27.8 million in Q1 2025 to a low of -$21.6 million in Q1 2021.
  • Average Change in Account Payables over 5 years is $676600.0, with a median of $2.1 million recorded in 2023.
  • Peak YoY movement for Change in Account Payables: tumbled 2242.74% in 2022, then skyrocketed 907.07% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at -$3.3 million in 2021, then soared by 236.99% to $4.5 million in 2022, then increased by 23.02% to $5.5 million in 2023, then skyrocketed by 69.04% to $9.3 million in 2024, then crashed by 233.76% to -$12.4 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Change in Account Payables are -$12.4 million (Q4 2025), $2.9 million (Q3 2025), and $2.6 million (Q2 2025).